- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen, Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: Novel perspectives on the pharmacological treatment of thyroid-associated ophthalmopathy. (Pubmed Central) - Jan 28, 2025
In addition, some drug candidates and molecular targets identified in the TAO in vitro model have shown promising prospects. This article briefly reviews the potential new strategies for future clinical treatment and the progress of new drug therapies for TAO.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Clinical, Journal: Re: Ugradar et (Pubmed Central) - Jan 17, 2025
This article briefly reviews the potential new strategies for future clinical treatment and the progress of new drug therapies for TAO. No abstract available
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Observational Characterization of the Retreatment Course of Patients With Thyroid Eye Disease. (Pubmed Central) - Jan 12, 2025
Understanding these factors could help predict which patients may require retreatment or chronic dosing with teprotumumab. Further studies are essential to advance our understanding of the immunomodulatory effects of teprotumumab, duration of its therapeutic benefit, and potential retreatment strategies to improve long-term patient outcomes.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Effects of Teprotumumab on Eyelid Retraction in Thyroid Eye Disease. (Pubmed Central) - Jan 3, 2025
Teprotumumab treatment improves upper and lower eyelid retraction. The improvement in MRD correlated positively with proptosis reduction, indicating the influence of globe position on eyelid position.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
P4 data, Journal, Adverse events, Real-world evidence, Real-world: Post-marketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment. (Pubmed Central) - Dec 17, 2024
Clinicians and pharmacists should be vigilant regarding these AEs. However, available data are currently insufficient, and further pharmacovigilance and surveillance are needed to fully understand this issue.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Retrospective data, Review, Journal: Comprehensive Comparisons of Different Treatments for Active Graves' Orbitopathy: A Systematic Review and Bayesian Model-Based Network Meta-Analysis. (Pubmed Central) - Dec 16, 2024
Teprotumumab emerges as potentially the most effective treatment for reducing inflammation and increasing overall response rates when compared to no treatment, oral mycophenolate combined with intravenous glucocorticosteroids appears to be the best one in improving proptosis. While some treatments raise safety concerns due to reported adverse events, oral methotrexate combined with intravenous glucocorticosteroids appear to offer a favorable balance between efficacy and safety among the evaluated treatments.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Clinical, Journal: Surgical Timing for Patients with Thyroid Eye Disease Treated with Teprotumumab: A Collaborative Multicenter Study. (Pubmed Central) - Dec 10, 2024
While some treatments raise safety concerns due to reported adverse events, oral methotrexate combined with intravenous glucocorticosteroids appear to offer a favorable balance between efficacy and safety among the evaluated treatments. Our study suggests that while the rate of regression may not differ significantly, the severity, clinical impact, and need for additional surgery might be more pronounced for patients who have surgery more than 6 months after their last teprotumumab dose.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Review, Journal: Teprotumumab versus intravenous methylprednisolone in thyroid eye disease: A systematic review. (Pubmed Central) - Dec 9, 2024
This systematic review provides an overview of the existing treatment options using monoclonal antibody - teprotumumab and IVMP in TED patients. The overall assessment provides a finding that antibody - teprotumumab is is a good choice compared to conventional IVMP for providing better outcomes in patients with TED.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Review, Journal: Advances of IGF-1R inhibitors in Graves' ophthalmopathy. (Pubmed Central) - Nov 23, 2024
Clinical trials have shown that teprotumumab reduces proptosis better than placebo, and may be beneficial for patients with worsening disease after steroid cessation. In this review, we discuss the role and prospects of IGF-1R inhibitors in thyroid-associated ophthalmopathy.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Teprotumumab for the treatment of Thyroid eye disease. (Pubmed Central) - Nov 21, 2024
Since 2020, over 5, 800 patients have been treated with teprotumumab and it appears to be well tolerated. The American Thyroid Association and the European Thyroid Association have recommended it as first line therapy for patients with moderate to severe TED, who display features of proptosis and diplopia.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Retrospective data, Review, Journal: Teprotumumab's Impact on Proptosis in Long-duration Thyroid Eye Disease: A Systematic Review and Meta-analysis. (Pubmed Central) - Nov 15, 2024
Further research is essential to understand teprotumumab's long-term efficacy and comparative advantages over surgical options. These findings have significant implications for treating persistent proptosis in patients with long-duration TED, potentially offering a non-surgical alternative where options were previously limited.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Biomarker, Retrospective data, Journal: Effects of teprotumumab and role of HLA markers in patients with thyroid eye disease. (Pubmed Central) - Nov 3, 2024
HLA may predict responders vs nonresponders. Further studies with longer duration and larger population comparing teprotumumab with steroids or other immunomodulatory agents (tocilizumab, rituximab, etc) may be helpful.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Trial completion date, Trial primary completion date: TEPEZZA (clinicaltrials.gov) - Oct 18, 2024
P4, N=313, Active, not recruiting,
However, before prescribing a drug, practitioners should assess its benefit/risk ratio based on the following: (i) evidence-based medicine; (ii) their empirical experience; (iii) the cost/benefit analysis; (iv) the long-term outcomes and safety profile. Trial completion date: Oct 2025 --> Apr 2026 | Trial primary completion date: Oct 2025 --> Apr 2026
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen, Actemra IV (tocilizumab) / Roche, JW Pharma
Journal: Survey of the management of moderate to severe active Graves' orbitopathy at 28 metropolitan centers of excellence in France (Pubmed Central) - Oct 6, 2024
This study highlights the variability in practices and the importance of a multidisciplinary approach, while calling for national standardization of practices. Despite disparities in the application of recommendations, the emergence of second-line treatments such as tocilizumab and teprotumumab indicates a steady evolution in therapeutic options, although obstacles in terms of accessibility and cost remain.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Impact of Teprotumumab on Clinical Practice in Thyroid Eye Disease. (Pubmed Central) - Oct 3, 2024
Teprotumumab introduction increased TED therapy evaluations, yet not all received recommended treatment due to safety concerns or accessibility issues. Enhancing collaborative care, medication accessibility, and adverse effect management is crucial.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Interleukin-11 Receptor Antibody, LASN01, May Be a Novel Treatment for TED, Regardless of Prior Treatment (DEMAND) - Sep 24, 2024 - Abstract #AAO2024AAO_2298;
P2
Conclusion The ability of LASN01 to inhibit HA was equivalent to teprotumumab in OF and was not impacted by any prior treatment or health characteristics. LASN01 is currently being evaluated in a Phase 2 study (NCT06226545) in patients with active TED, including a cohort of patients with prior teprotumumab treatment, and this may offer a differentiated treatment option based on the data generated in OF.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Interleukin-11 Receptor Antibody, LASN01, Blocks Fibroinflammatory Drivers in TED (DEMAND) - Sep 24, 2024 - Abstract #AAO2024AAO_2297;
P2
Conclusion IL-11 may be a novel mediator in TED, and IL-11R inhibition with LASN01 has the potential to target multiple pathogenic mechanisms. A Phase 2 study with LASN01 is currently open for patients with TED (NCT06226545), including those previously treated with teprotumumab.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
SD-OCT Imaging Findings in Patients Receiving Teprotumumab for TED (DEMAND) - Sep 24, 2024 - Abstract #AAO2024AAO_2296;
Conclusion There were significant decreases in choroidal, RNFL and GCC thickness in TED patients treated with teprotumumab. Further research is needed to understand the full effect of retinal IGF-1R blockade.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Untangling Teprotumumab's Adverse Events Through a National Analysis (POSTER THEATER) - Sep 24, 2024 - Abstract #AAO2024AAO_1829;
Conclusion Besides teprotumumab's previously described AEs, we found positive signals for lesser-described events, like increased blood pressure, permanent deafness and diverticulitis. Further investigation is needed.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Identified Risks and Stratification for Teprotumumab-Associated Chronic Ototoxicty (S405) - Sep 24, 2024 - Abstract #AAO2024AAO_1674;
Conclusion Teprotumamab-induced chronic ototoxicty occurs when patients have baseline hearing loss or demonstrate decline by the midpoint of therapy or are elderly, current smokers or super proptosis responders. Determining patients at risk will be beneficial in determining who may be likely to experience chronic ototoxicty and obviating comorbidity.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Review, Journal: Patterns of Teprotumumab-Induced Hearing Dysfunction: A Systematic Review. (Pubmed Central) - Aug 28, 2024
Hearing loss occurs primarily in higher frequencies, and routine hearing screening with ultrahigh frequency testing may be warranted. The true incidence of ototoxicity with teprotumumab remains unknown, and more data is needed to elucidate underlying mechanisms and develop strategies to minimize risks.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease. (Pubmed Central) - Aug 26, 2024
In this retrospective study analysing proptosis change as a percentage of pre-treatment proptosis among 119 patients, 208 (87.4%) eyes of 110 patients had proptosis reduction averaging 14.4% (range 2.2-40.5%) of their pre-treatment proptosis, or 3.3?mm (range 0.5-10.0?mm). Reporting proptosis reduction as a percentage of pre-treatment proptosis provides a better understanding of teprotumumab's clinical impact.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: "Teprotumumab for inactive thyroid eye disease? The jury is still out.". (Pubmed Central) - Aug 12, 2024
The results of this study highlight the potential for teprotumumab therapy in this subgroup and also provide a unique insight into the potential role of the IGF-1R in these patients. No abstract available
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Reversible cerebral vasoconstriction syndrome due to teprotumumab: two case reports. (Pubmed Central) - Aug 9, 2024
The temporal correlation between teprotumumab initiation and RCVS's symptom onset raises concern for the potential involvement of teprotumumab in triggering RCVS via disrupting cerebrovascular modulation. Further research is needed to investigate this proposed association.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Review, Journal: Thyroid Eye Disease: Advancements in Orbital and Ocular Pathology Management. (Pubmed Central) - Jul 27, 2024
The introduction of Teprotumumab, the first FDA-approved drug specifically for TED, marks a pivotal development in medical therapy...Future directions in TED treatment include emerging pharmacological therapies targeting different aspects of the disease's pathophysiology and advanced surgical techniques aimed at enhancing precision and safety. This review underscores the importance of a personalized, multidisciplinary approach in managing TED, highlighting current advancements, and exploring potential future innovations to improve patient outcomes and quality of life.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Orbital decompression following treatment with teprotumumab for thyroid eye disease. (Pubmed Central) - Jul 27, 2024
While the number of TED patients treated at one tertiary care center has risen over recent years, the number of orbital decompression surgeries has declined. Orbital decompression, however, is still needed in select patients after treatment with teprotumumab.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Observational data, Journal: An observational study on the safety of teprotumumab based on FAERS database. (Pubmed Central) - Jul 13, 2024
Trial completion date: Mar 2026 --> Sep 2025 Clinical application of teprotumumab should be closely monitored for ototoxicity, nail abnormalities, and menstrual changes, as well as for AEs not mentioned in the drug instruction, including gingival recession, thyroid-stimulating immunoglobulin increase, and so on.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Retrospective data, Journal: Teprotumumab for Thyroid Eye Disease-related Strabismus. (Pubmed Central) - Jul 10, 2024
Extraocular motility in all 4 ductions also improved. A substantial minority of patients still required strabismus surgery following teprotumumab.
|
